136 related articles for article (PubMed ID: 19618998)
1. Dynamics of raltegravir resistance profile in an HIV type 2-infected patient.
Xu L; Anderson J; Garrett N; Ferns B; Wildfire A; Cook P; Workman J; Graham S; Smit E
AIDS Res Hum Retroviruses; 2009 Aug; 25(8):843-7. PubMed ID: 19618998
[TBL] [Abstract][Full Text] [Related]
2. Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.
Charpentier C; Larrouy L; Matheron S; Damond F; Delelis O; Mouscadet JF; Campa P; Chêne G; Brun-Vézinet F; Descamps D;
Antivir Ther; 2011; 16(6):937-40. PubMed ID: 21900727
[TBL] [Abstract][Full Text] [Related]
3. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
Canducci F; Sampaolo M; Marinozzi MC; Boeri E; Spagnuolo V; Galli A; Castagna A; Lazzarin A; Clementi M; Gianotti N
AIDS; 2009 Feb; 23(4):455-60. PubMed ID: 19165083
[TBL] [Abstract][Full Text] [Related]
4. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
Requena S; Treviño A; Cabezas T; Garcia-Delgado R; Amengual MJ; Lozano AB; Peñaranda M; Fernández JM; Soriano V; de Mendoza C;
J Antimicrob Chemother; 2017 Jul; 72(7):2083-2088. PubMed ID: 28369593
[TBL] [Abstract][Full Text] [Related]
5. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.
Charpentier C; Karmochkine M; Laureillard D; Tisserand P; Bélec L; Weiss L; Si-Mohamed A; Piketty C
HIV Med; 2008 Oct; 9(9):765-70. PubMed ID: 18651855
[TBL] [Abstract][Full Text] [Related]
6. G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.
Ni XJ; Delelis O; Charpentier C; Storto A; Collin G; Damond F; Descamps D; Mouscadet JF
Retrovirology; 2011 Aug; 8():68. PubMed ID: 21854605
[TBL] [Abstract][Full Text] [Related]
7. The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy.
Ferns RB; Kirk S; Bennett J; Cook PM; Williams I; Edwards S; Pillay D
AIDS; 2009 Oct; 23(16):2159-64. PubMed ID: 19571721
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimens.
Nguyen HL; Charpentier C; Nguyen N; de Truchis P; Molina JM; Ruxrungtham K; Delaugerre C
HIV Med; 2013 Feb; 14(2):85-91. PubMed ID: 22994529
[TBL] [Abstract][Full Text] [Related]
9. HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.
Cavaco-Silva J; Abecasis A; Miranda AC; Poças J; Narciso J; Águas MJ; Maltez F; Almeida I; Germano I; Diniz A; Gonçalves Mde F; Gomes P; Cunha C; Camacho RJ;
PLoS One; 2014; 9(3):e92747. PubMed ID: 24681625
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
da Silva D; Van Wesenbeeck L; Breilh D; Reigadas S; Anies G; Van Baelen K; Morlat P; Neau D; Dupon M; Wittkop L; Fleury H; Masquelier B
J Antimicrob Chemother; 2010 Jun; 65(6):1262-9. PubMed ID: 20388636
[TBL] [Abstract][Full Text] [Related]
11. Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
Roquebert B; Blum L; Collin G; Damond F; Peytavin G; Leleu J; Matheron S; Chêne G; Brun-Vézinet F; Descamps D;
AIDS; 2008 Oct; 22(15):2045-6. PubMed ID: 18784469
[No Abstract] [Full Text] [Related]
12. Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.
Fun A; Leitner T; Vandekerckhove L; Däumer M; Thielen A; Buchholz B; Hoepelman AIM; Gisolf EH; Schipper PJ; Wensing AMJ; Nijhuis M
Retrovirology; 2018 Jan; 15(1):1. PubMed ID: 29304821
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure.
Fernández-Caballero JÁ; Chueca N; Álvarez M; Mérida MD; López J; Sánchez JA; Vinuesa D; Martínez MÁ; Hernández J; García F
BMC Infect Dis; 2016 May; 16():197. PubMed ID: 27177767
[TBL] [Abstract][Full Text] [Related]
14. Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations.
Garrido C; de Mendoza C; Alvarez E; García F; Morello J; Garcia S; Ribera E; Rodríguez-Novoa S; Gutierrez F; Soriano V;
AIDS Res Hum Retroviruses; 2012 Feb; 28(2):156-64. PubMed ID: 21457126
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.
Gutiérrez C; Hernández-Novoa B; Pérez-Elías MJ; Moreno AM; Holguín A; Dronda F; Casado JL; Moreno S
HIV Clin Trials; 2013; 14(1):10-6. PubMed ID: 23372110
[TBL] [Abstract][Full Text] [Related]
16. Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir.
Huang W; Frantzell A; Fransen S; Petropoulos CJ
Antimicrob Agents Chemother; 2013 Sep; 57(9):4105-13. PubMed ID: 23733474
[TBL] [Abstract][Full Text] [Related]
17. Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.
Passaes CP; Guimarães ML; Cardoso SW; Pilotto JH; Veloso V; Grinsztejn B; Morgado MG
J Med Virol; 2012 Dec; 84(12):1869-75. PubMed ID: 23080489
[TBL] [Abstract][Full Text] [Related]
18. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.
Malet I; Delelis O; Valantin MA; Montes B; Soulie C; Wirden M; Tchertanov L; Peytavin G; Reynes J; Mouscadet JF; Katlama C; Calvez V; Marcelin AG
Antimicrob Agents Chemother; 2008 Apr; 52(4):1351-8. PubMed ID: 18227187
[TBL] [Abstract][Full Text] [Related]
19. Structure-analysis of the HIV-1 integrase Y143C/R raltegravir resistance mutation in association with the secondary mutation T97A.
Reigadas S; Masquelier B; Calmels C; Laguerre M; Lazaro E; Vandenhende M; Neau D; Fleury H; Andréola ML
Antimicrob Agents Chemother; 2011 Jul; 55(7):3187-94. PubMed ID: 21576445
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir.
Bercoff DP; Triqueneaux P; Lambert C; Oumar AA; Ternes AM; Dao S; Goubau P; Schmit JC; Ruelle J
Retrovirology; 2010 Nov; 7():98. PubMed ID: 21114823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
